LIXTE Begins Clinical Trial for Colorectal Cancer Treatment
First Patient Dosed with LIXTE’s LB-100 in Clinical Trial
PASADENA, Calif. — LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) has announced that the first patient has been dosed in a promising new clinical trial aimed at treating unresponsive (MSI Low) metastatic colorectal cancer. This study is being conducted in collaboration with the Netherlands Cancer Institute (NKI) and is supported by F. Hoffmann-La Roche Ltd. (“Roche”).
Details of the Clinical Trial
This clinical trial, identified as NCT06012734, involves the use of LIXTE's lead compound, LB-100, along with Roche's atezolizumab (Tecentriq), which is a PDL1 inhibitor. The study is part of the imCORE Network, a global initiative that fosters academic and industry collaboration to expedite cancer immunotherapy research.
Objective of the Trial
The primary goal of this clinical trial is to assess the efficacy of immunotherapy in treating approximately 85 percent of colorectal cancer patients who have not previously responded to conventional treatment protocols. Dr. Neeltje Steeghs, a medical oncologist at NKI, emphasized the trial's aim to introduce effective treatment options for this patient population.
CEO's Statement on the Trial Start
Bas van der Baan, CEO of LIXTE, expressed satisfaction with the initiation of this significant trial, which has been funded by Roche. He highlighted that this marks the second clinical trial where LB-100 will be combined with immunotherapy and funded by a leading pharmaceutical company, after the recent collaboration with GSK targeting clear cell ovarian cancer.
About LIXTE Biotechnology Holdings, Inc.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company committed to the development of new cancer therapies. Its groundbreaking lead compound, LB-100, known for its ability to inhibit PP2A, has demonstrated a good safety profile and potential anti-cancer effects in patients. Researchers have carefully evaluated its capabilities, and early findings are promising for enhancing existing chemotherapies and immunotherapy regimens.
Innovative Approach to Cancer Treatment
The company is pioneering a novel approach to cancer treatment that involves the concept of activation lethality, which aims to reshape the therapeutic strategies for various cancers, including colorectal, ovarian, and sarcoma cancers. LIXTE's strategy is supported by a robust patent portfolio, ensuring the protection of its innovative processes.
Additional Information and Contacts
For further information about LIXTE, potential investors or interested parties can reach out via the following contact methods:
Contact Information:
Email: info@lixte.com
General Phone: (631) 830-7092; Investor Phone: (888) 289-5533
Additionally, inquiries can be directed towards PondelWilkinson Inc. Investor Relations at pwinvestor@pondel.com.
Roger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962
Frequently Asked Questions
What is the purpose of the clinical trial involving LB-100?
The trial aims to evaluate the effectiveness of LB-100 combined with atezolizumab for treating unresponsive metastatic colorectal cancer.
Which organizations are collaborating on this clinical trial?
The clinical trial is a collaboration between LIXTE Biotechnology Holdings, Inc. and the Netherlands Cancer Institute, with support from Roche.
What is LB-100?
LB-100 is LIXTE's lead compound that inhibits PP2A, which has shown potential in enhancing anticancer therapies.
How does this trial fit into LIXTE's broader strategy?
This trial represents a strategic initiative for LIXTE to integrate its innovative treatment approaches within the developing landscape of cancer immunotherapy.
What other clinical trials is LIXTE currently conducting?
LIXTE is also conducting clinical trials targeting other cancers, including ovarian and sarcoma cancers.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Advanced Digital Twin Solutions Projected to Transform Logistics
- BlackRock Adjusts Shareholding in Novonesis for Growth Strategy
- Revamping Expectations: AngioDynamics Prepares for Earnings Release
- BofA Adjusts STMicroelectronics Forecast Amid Market Challenges
- Optimistic Forecast for JSW Steel Amid Capacity Expansion Plans
- ASEAN+3 Growth Forecasts Highlight Resilience in Economy
- Stora Enso Strategizes Divestment of Forest Assets
- Novo Nordisk Faces Asymmetrical Risks With Upcoming Trial Results
- Market Reactions to Middle East Conflict and Tesco's Strong Performance
- Mentimeter Selected as Key Tool for Engaging at SXSW 2024
Recent Articles
- Fiverr Leadership to Speak at Major Tech Conference
- Anterix to Showcase Innovations at Gateway Conference 2024
- Asia Pacific Wire & Cable Corporation Limited Q2 2024 Results
- EXL to Present at Citi Global TMT Conference in New York
- Comscore and FreeWheel Enhance CTV Advertising Partnership
- Fly Play hf Enters Strategic Market-Making Agreement
- Free Flow, Inc. (FFLO) Acquires Pharmaceutical Business
- DMZ Basecamp Awards Over $50,000 to Student Startups
- Dr. Shams Tabrez Joins GI Alliance to Enhance Patient Care
- SEALSQ Advances IoT Data Security with Swiss Data Centers
- Understanding AGI and Its Impact on Social Security Benefits
- Nvidia's Upcoming Earnings: What Investors Need to Know
- IPS Displays Market Growth to USD 120.56 Billion by 2032
- Transformative Impact of DSPM on Data Security Landscape
- Market Surge Expected as Fed Prepares for Interest Rate Cuts
- Beldex Network's Hermes Hardfork: Enhancing Privacy & Security
- Rhythm Pharmaceuticals to Speak at Healthcare Conference
- Esperion to Engage in H.C. Wainwright Investment Conference
- G2 Goldfields Showcases Strong Year-End Financial Results
- Scorpius Holdings Updates on Expanded Sales and Manufacturing
- Meridianbet Shortlisted for Exclusive License in Brazil
- Vital Farms Welcomes Reena Van Hoven as CPO
- BullFrog AI Engages at H.C. Wainwright Investment Conference
- LifeVantage Unveils Innovative Weight Management Solution
- Halberd Corp Highlights Exciting Advancements in TBI Treatment
- Biora Therapeutics at H.C. Wainwright Investment Conference
- CarnoSyn® Brands Unveils TriBsyn™ at ESPEN Congress
- STMicroelectronics Updates Share Repurchase Program Status
- DIRTT Environmental Solutions Launches NCIB for Debentures
- FlexShopper Joins Forces with Terrace Finance for Merchant Solutions
- Rhythm Pharmaceuticals Advances IMCIVREE® for Young Patients
- Velcan Holdings Weekly Share Buyback Update
- Morgan Stanley Acquires Major Stake in NKT A/S
- Nano Dimension Receives HSR Clearance for Desktop Metal Acquisition
- Life Science Analytics Market Trends and Growth Opportunities
- Global Healthcare Distribution Market Analysis and Insights
- Blockchain Revolutionizes Cold Chain Logistics Market Growth
- Columbia Financial Gains Regulatory Approval for Merger
- Hivello Partners with Mysterium to Enhance Decentralized Income
- Retiring Early: Feasibility of $3 Million at Age 45
- Vericel Receives FDA Approval for MACI Arthro Technology
- Elevai Labs Reports Positive Clinical Study Results
- Golconda Gold Ltd. Financial Results for Q2 2024
- Euro Manganese Collaborates with Blue Grass Chemical
- FutureFuel Honors Tom McKinlay for His Leadership
- BridgeBio Innovates ATTR-CM Diagnosis with AI Partnership
- Alarum Technologies Reports Record Second Quarter 2024 Results
- Hillman Solutions Corp. Expands with Intex DIY Acquisition
- Minerals Technologies to Present at Upcoming Investor Conferences
- Why Realty Income is the Ideal Investment for Income Seekers